RxDoctor Payments Data

Parag Majmudar, MD

Ophthalmology · Highland Park, ILNPI 1912988981

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 24.6% of the total. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$450,703in general payments, 2019–2025

Across 742 payments — averaging $607.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$111K
  • Dompe US, Inc.$53K
  • Sun Pharmaceutical Industries Inc.$49K
  • Alcon$49K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$43K
  • Kala Pharmaceuticals, Inc.$40K
  • plus $105K from 31 others
$108,555in research payments, 2019–2025

Across 59 payments — averaging $1839.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Oyster Point Pharma, Inc.$24K
  • Alcon Research LLC$23K
  • Kala Pharmaceuticals, Inc.$22K
  • AbbVie$19K
  • Sun Pharmaceutical Industries Inc.$14K
  • Kowa Research Institute, Inc.$4K
  • plus $2K from 1 others

What the payments were for

  • Consulting fees$139,98731%
  • Speaking & faculty fees$241,56954%
  • Grants$2,0210%
  • Travel & lodging$41,9839%
  • Food & beverage$25,1046%
  • Education$40%
  • Gifts$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$450,703 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$338,076
Medicare patients
868
Services billed
2,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine18$22,229
Prednisolone Acetate530$15,061
VevyeCyclosporine16$11,785
Ketorolac Tromethamine208$7,887
Loteprednol Etabonate53$7,138
Cyclosporine12$6,103
Ofloxacin210$2,114
Latanoprost164$1,613
ValacyclovirValacyclovir Hcl18$1,240
Epinastine Hcl11$610
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat31$550
Timolol Maleate37$341
Brimonidine Tartrate16$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$3,902$22,22918 claims
Harrow Eye, LLCVevye$631$11,78516 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$43,321$7,13853 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Highland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →